New long‑term results from the RUBY clinical trial show that adding immunotherapy (dostarlimab) to chemotherapy may help some ...

Newark, New Castle, USA, May 24, 2023 (GLOBE NEWSWIRE) -- The market analysis of the global dostarlimab-gxly market was conducted by Growth Plus Reports in 2022. The market is expected to hit a ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

In the overall study population, treatment with dostarlimab-gxly plus chemotherapy reduced the risk of death by 31% vs placebo plus chemotherapy. The Food and Drug Administration (FDA) has accepted ...

For patients with primary advanced or recurrent endometrial cancer, dostarlimab plus carboplatin-paclitaxel increases progression-free survival versus carboplatin-paclitaxel alone, according to a ...

The results of a small clinical trial have found that there could be a cure for rectal cancer. The trial — conducted by Memorial Sloan Kettering Cancer Center in Manhattan — involved at least 12 ...

Here are 10 things to know about Dostarlimab, the drug that cured cancer during trial: The clinical trial comprised a group of 18 patients. All of them were battling rectal cancer at the Memorial ...

Jemperli (dostarlimab) becomes the first immunotherapy treatment to receive NICE recommendation for use, in line with its license, in eligible endometrial cancer patients in first line setting GSK plc ...

DAEJEON, South Korea, Jan. 20, 2026 /PRNewswire/ -- Alteogen Inc. (KOSDAQ: 196170) announced today that the company has entered into an exclusive license agreement with Tesaro, Inc., a subsidiary of ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

In a prospective phase II study that involved patients with mismatch repair–deficient locally advanced rectal cancer, treatment with neoadjuvant single-agent, PD1 inhibitor dostarlimab resulted in a ...